Cellectar Biosciences
CLRB
37 hedge funds and large institutions have $28.3M invested in Cellectar Biosciences in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 13 closing their positions.
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
1.4% less ownership
Funds ownership: 2.48% → 1.08% (-1.4%)
18% less funds holding
Funds holding: 45 → 37 (-8)
22% less capital invested
Capital invested by funds: $36.3M → $28.3M (-$8.08M)
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
95% less call options, than puts
Call options by funds: $8K | Put options by funds: $151K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$6.67M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.19M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$740K |
| 4 |
BlackRock
New York
|
+$277K |
| 5 |
Morgan Stanley
New York
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIP
Lighthouse Investment Partners
Palm Beach Gardens,
Florida
|
-$552K |
| 2 |
Barclays
London,
United Kingdom
|
-$531K |
| 3 |
Renaissance Technologies
New York
|
-$392K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$233K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$216K |
CLRB Hedge Fund Activity: Q2 2024 in Review
37 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2024, worth a combined $28.3M — down 22% from $36.3M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLRB and 5 opened new positions — a net loss of 8 holders — while 8 trimmed existing stakes and 17 added.
The largest buyer was Rosalind Advisors, adding an estimated $6.67M. The largest seller was Lighthouse Investment Partners, exiting entirely with an estimated $552K sold.
- 37 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2024, down from 45 in Q1 2024.
- Funds reported $28.3M of Cellectar Biosciences stock for Q2 2024, down 22% quarter-over-quarter.
- 5 funds opened new Cellectar Biosciences positions in Q2 2024 and 13 closed out, a net change of -8 holders.
- The largest Cellectar Biosciences buyer in Q2 2024 was Rosalind Advisors, an estimated $6.67M added.
- The largest Cellectar Biosciences seller in Q2 2024 was Lighthouse Investment Partners, an estimated $552K sold.
Based on aggregated 13F filings for Q2 2024.